High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis


Abstract

Background—High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 have been identified as novel antigens of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCAs), and the existence of anti-HMG1 and anti-HMG2 antibodies in a population of patients with ulcerative colitis has been reported.

Aims—To investigate whether HMG1 and HMG2 are target antigens for p-ANCAs in autoimmune hepatitis (AIH).

Patients—Serum samples from 28 patients with AIH, 44 patients with primary biliary cirrhosis (PBC), 27 patients with chronic hepatitis C, and 23 patients with chronic hepatitis B were tested.

Methods—ANCAs were detected by routine indirect immunofluorescence (IIF). Anti-HMG1 and anti-HMG2 antibodies were assayed by enzyme linked immunosorbent assay.

Results—p-ANCAs were detected in 89% (25/28) of patients with AIH, 36% (16/44) of patients with PBC, 11% (3/27) of patients with chronic hepatitis C, and 13% (3/23) of patients with chronic hepatitis B. Anti-HMG1 and/or anti-HMG2 antibodies were detected in 89% (25/28) of patients with AIH, 79% (31/41) with PBC, 26% (7/27) with chronic hepatitis C, and 9% (2/23) with chronic hepatitis B. In AIH, anti-HMG1 and/or anti-HMG2 antibodies were detected in 96% (24/25) of p-ANCA positive patients. The p-ANCA staining pattern detected by IIF using sera from patients with AIH disappeared or decreased in titre after preincubation with a mixture of HMG1/HMG2. The presence and titres of those antibodies in AIH correlated significantly with those of p-ANCA, but not with those of antinuclear antibody or anti-smooth muscle antibody.

Conclusions—HMG1 and HMG2 are significant target antigens of p-ANCA in AIH.

Gut 1999;44:867–873

Keywords: perinuclear anti-neutrophil cytoplasmic antibodies; chromosomal proteins; high mobility group 1 and 2; autoimmune; hepatitis

Anti-neutrophil cytoplasmic antibodies (ANCAs) are directed against the cytoplasmic components of neutrophils. They can be divided into two major subtypes by indirect immunofluorescence (IIF) using ethanol fixed neutrophils as substrates; those showing a cytoplasmic pattern (c-ANCAs) and those showing a perinuclear pattern (p-ANCAs). Most c-ANCAs are specific for proteinase 3,4 and a substantial proportion of p-ANCAs are directed against myeloperoxidase.4 The strong association of ANCs with systemic vasculitis has been established: proteinase 3-ANCAs are more commonly found in patients with Wegener’s granulomatosis5–7 and myeloperoxidase-ANCAs are more commonly found in patients with vasculitis limited to the kidney.7 p-ANCAs have been associated not only with systemic vasculitis but also with non-vasculitic diseases, such as inflammatory bowel disease9–13 and chronic liver diseases.14 In autoimmune liver diseases, particularly autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC), p-ANCAs are commonly detected. These p-ANCAs do not react with myeloperoxidase, and it has been speculated that their target antigens are different from the granule proteins of neutrophils reported previously.5–11 Recent studies have reported that actin is one of the target antigens of ANCs in AIH14 and that catalase and α-enolase are those in PSC.15 However, the main target antigens remain unclear.

Recently, we identified high mobility group (HMG) non-histone chromosomal proteins, HMG1 and HMG2 as novel antigens of p-ANCAs, and reported the existence of anti-HMG1/HMG2 antibodies in a population of patients with ulcerative colitis15–18 and systemic rheumatic diseases19 HMG1 and HMG2, which are distributed not only in the nuclei but also in the cytoplasm of eukaryotic cells.

Abbreviations used in this paper: ANCA, anti-neutrophil cytoplasmic antibody; IIF, indirect immunofluorescence; c-ANCA, cytoplasmic anti-neutrophil cytoplasmic antibody; p-ANCA, perinuclear anti-neutrophil cytoplasmic antibody; AIH, autoimmune hepatitis; PSC, primary sclerosing cholangitis; HMG, high mobility group; ELISA, enzyme linked immunosorbent assay; PBC, primary biliary cirrhosis; ANA, anti-nuclear antibody; SMA, anti-smooth muscle antibody; AMA, anti-mitochondrial antibody.

Downloaded from http://gut.bmj.com/ on June 21, 2017 - Published by group.bmj.com
cells, are known to act as transcriptional factors. In spite of their ubiquitous distribution, we found that some monoclonal anti-HMG1/HMG2 antibodies showed a perinuclear staining pattern of ethanol-fixed neutrophils on IIF, and that these antibodies did not stain lymphocytes or HEp-2 cells. These results indicate that antibodies against HMG1 and HMG2 fulfill the criteria of p-ANCA. Interestingly, in western blotting using neutrophils, these antibodies exhibited different bands from those using lymphocytes or HEp-2 cells (unpublished observation), suggesting that HMG1 and HMG2 in neutrophils may be distinct from those in lymphocytes or HEp-2 cells.

The amino acid sequences of HMG1/HMG2 are highly conserved among species—for instance, there are only two amino acid differences between human and porcine HMG1/HMG2. Because of this high degree of conservation in primary sequences, anti-human HMG1/HMG2 sera cross reacted with porcine HMG1 and HMG2. Therefore we established an enzyme-linked immunosorbent assay (ELISA) system using porcine HMG1/HMG2 as antigens instead of human proteins.

In this study, we studied the prevalence of anti-HMG1/HMG2 antibodies in chronic liver diseases—that is, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and chronic hepatitis C and B, using the ELISA system and analysed the relations between anti-HMG1/HMG2 antibodies and p-ANCA in these diseases. Furthermore, we analysed the relations between anti-HMG1/HMG2 antibodies and antibodies to cathepsin G and lactoferrin, which are reported to be target antigens of p-ANCA, and other autoantibodies such as anti-nuclear antibody (ANA), anti-smooth muscle antibody (SMA), and anti-mitochondrial antibody (AMA), which are useful seromarkers for AIH or PBC.

Patients and methods

PATIENTS

Sera from 28 patients with AIH and 44 patients with PBC were studied (table 1). The diagnoses of AIH and PBC were made on the basis of clinical, serological, and histological criteria. All 28 patients with AIH lacked other causes of chronic liver disease such as metabolic, drug related, and viral including hepatitis A, hepatitis B, and hepatitis C virus. All patients had persistent elevation of serum aminotransferases, IgG (>2500 mg/dl), and non-organ-specific autoantibodies. In all cases, liver biopsy specimens showed moderate or severe piecemeal necrosis and inflammatory mononuclear cell infiltration into the portal tract. Seven patients had other immunological diseases: two had Sjögren’s syndrome, one had Sjögren’s syndrome and chronic thyroiditis, one had chronic thyroiditis, one had rheumatoid arthritis, one had rheumatoid arthritis and systemic sclerosis, and one had systemic sclerosis. The activity index was determined according to the definition of the international autoimmune hepatitis group. Five patients had been treated with prednisolone (5–40 mg/day) at the time of blood sampling.

All 44 patients with PBC had cholestatic liver disease. Thirty one patients showed chronic non-suppurative destructive cholangitis on liver biopsy specimens. The remaining 13 were positive for serum AMA and/or antipyruvate dehydrogenase antibody and showed liver histology compatible with PBC. Twelve patients had other immunological diseases: five had Sjögren’s syndrome, one had Sjögren’s syndrome and rheumatoid arthritis, two had Sjögren’s syndrome and systemic sclerosis, one had systemic sclerosis, two had systemic sclerosis and chronic thyroiditis, and one had chronic thyroiditis. One patient had been treated with prednisolone (10 mg/day) at the time of blood sampling.

As disease controls, we tested sera from patients with chronic viral hepatitis: 27 patients with chronic hepatitis C and 23 with chronic hepatitis B diagnosed by liver biopsy and serology (second generation assays). Twenty four age matched healthy blood donors served as normal controls. Informed consent was obtained from each subject. The sample sera were stored at −20°C.

MATERIALS

Porcine HMG1 and HMG2 were purified from pig thymus as described elsewhere. Human cathepsin G (ICN Biomedicals, Cleveland, Ohio, USA) and human lactoferrin (Sigma, St Louis, Missouri, USA) were purchased. Their

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>AIH</th>
<th>PBC</th>
<th>Viral hepatitis C</th>
<th>Viral hepatitis B</th>
<th>Normal controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of patients and controls</td>
<td>28</td>
<td>44</td>
<td>27</td>
<td>23</td>
<td>24</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>6/22</td>
<td>4/40</td>
<td>15/12</td>
<td>15/8</td>
<td>8/16</td>
</tr>
<tr>
<td>Median age (years)*</td>
<td>52 (24–80)</td>
<td>60 (36–71)</td>
<td>53 (30–62)</td>
<td>30 (20–56)</td>
<td>51 (34–77)</td>
</tr>
<tr>
<td>Other immunological diseases†</td>
<td>7 (25)</td>
<td>12 (27)</td>
<td>1 (4)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>(concomitant presence of UC)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Positive AMA (&gt;1:40)†</td>
<td>25 (89)</td>
<td>29 (66)</td>
<td>2 (7)</td>
<td>1 (4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Positive SMA (&gt;1:40)†</td>
<td>16 (57)</td>
<td>1 (2)</td>
<td>6 (22)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Positive AMA (&gt;1:40)†</td>
<td>3 (11)</td>
<td>33 (75)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Presence of cirrhosis†</td>
<td>3 (11)</td>
<td>11 (25)</td>
<td>4 (15)</td>
<td>13 (5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Use of prednisolone at the time of sampling†</td>
<td>5 (18)</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

*Data in parentheses represent ranges.
†Data expressed as number of patients (percentage of whole).
AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; UC, ulcerative colitis; ANA, anti-nuclear antibody; SMA, anti-smooth muscle antibody; AMA, anti-mitochondrial antibody.
purity was confirmed by sodium dodecyl sulphate/polyacrylamide gel electrophoresis. Neutrophils were isolated from peripheral blood obtained from normal human volunteers by Ficoll density gradient centrifugation. Affinity purified anti-HMG1/HMG2 antibody was obtained by applying the serum from a p-ANCA positive patient to an HMG1/HMG2 affinity column.

IIF ASSAY
ANCA activity was determined by IIF assay as described by Wiik. Briefly, ethanol fixed cytospin preparations of human neutrophils were incubated with serum at room temperature for 20 minutes at an initial dilution of 1:10 or 1:125 in phosphate buffered saline and in twofold dilutions thereof. As the secondary antibody, fluorescein isothiocyanate conjugated F(ab’)2 rabbit anti-human IgG (Serotec, Oxford, UK) was used. The slides were evaluated by fluorescence microscopy. ANCA titres were determined as the reciprocals of final dilutions to give positive staining. As controls, p-ANCA and c-ANCA positive sera were purchased from Binding Site (Birmingham, UK). Samples positive for perinuclear or nuclear staining were subjected to formalin fixation, instead of ethanol fixation, to distinguish ANCAs from antibodies to neutrophil nuclei. p-ANCAs were regarded as positive when they showed perinuclear or nuclear staining on ethanol fixed neutrophils and cytoplasmic or negative staining on formalin fixed neutrophils. Competitive inhibition IIF using an HMG1/HMG2 mixture was performed to determine the specificity of reactivity to HMG1/HMG2. Double positive sera for p-ANCA and anti-HMG1/HMG2 antibodies were diluted at optimal dilutions that were 8- or 16-fold more concentrated than their final dilutions to give p-ANCA positive staining. These sera were preincubated with equal volumes of HMG1/HMG2 mixture (100 µg/ml) or phosphate buffered saline for 30 minutes at room temperature, and were used for subsequent IIF assays in parallel to determine the ANCA titres. ANA, SMA, and AMA were assayed by IIF using commercial kits: fluoro HEPANA test for ANA, and fluoro AID-1 test for SMA and AMA (MBL, Nagoya, Japan). Sera were considered positive for ANA, SMA, and AMA at a dilution of ≥1:40.

Figure 1  Perinuclear anti-neutrophil cytoplasmic antibody activities on indirect immunofluorescence. Sera from patients with autoimmune hepatitis (A, B) and primary biliary cirrhosis (C, D), and an affinity purified anti-HMG1/HMG2 antibody (E, F) showing perinuclear staining on ethanol fixed neutrophils (A, C, E) and cytoplasmic or negative staining on formalin fixed neutrophils (B, D, F).
ELISA

Antibodies to HMG1, HMG2, cathepsin G, and lactoferrin were assayed by ELISA as described elsewhere. Briefly, 50 µl of 5 µg/ml HMG1 and HMG2 in phosphate buffered saline, pH 7.4, cathepsin G in 500 mM sodium acetate with 150 mM NaCl, pH 5.5, and lactoferrin in bicarbonate buffer, pH 9.6, were respectively put on microtitre plates (Immuno-plate maxisorp; Nunc, Roskilde, Denmark).

Serum samples were diluted 1:40 in phosphate buffered saline containing 5% bovine serum albumin, and the secondary antibody used was alkaline phosphatase conjugated F(ab')2 goat anti-human IgG (Immunotech, Marseille, France). Antibody titres were expressed as U/ml by reference to the dilution curves for positive control sera, the titres of which were arbitrarily set at 100 U/ml. A level >3 SD above the mean for normal sera was regarded as positive. Competitive inhibition ELISA using HMG1, HMG2, cathepsin G, and lactoferrin was performed to determine the specificity of reactivity to the respective proteins. The corresponding antibody positive sera at optimal dilutions were preincubated with equal volumes of HMG1, HMG2, cathepsin G, and lactoferrin of various concentrations for 30 minutes at room temperature. Ovalbumin was used as a control.

STATISTICAL ANALYSIS

The results were analysed by the Mann-Whitney U test, Wilcoxon signed rank test, Fisher’s exact test, and the Spearman rank correlation test. In these analyses, values of p<0.05 were considered statistically significant.

Results

DETECTION OF ANCAs BY IIF

ANCAs were tested by IIF in serum from patients with chronic liver diseases. p-ANCAs were detected in 25 (89%) of 28 sera from patients with AIH, 16 (36%) of 44 from patients with PBC, three (11%) of 27 from patients with chronic hepatitis C, and three (13%) of 23 from patients with chronic hepatitis B. Among the sera with positive perinuclear

<table>
<thead>
<tr>
<th>Disease (n)</th>
<th>p-ANCA (n)</th>
<th>HMG1</th>
<th>HMG2</th>
<th>HMG1 or 2*</th>
<th>HMG1 and 2†</th>
<th>Cathepsin G</th>
<th>Lactoferrin</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIH (28)</td>
<td>Positive (25)</td>
<td>22</td>
<td>23‡</td>
<td>24§</td>
<td>21</td>
<td>23</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Negative (3)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>PBC (44)</td>
<td>Positive (16)</td>
<td>12</td>
<td>12</td>
<td>13</td>
<td>11</td>
<td>15</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Negative (28)</td>
<td>14</td>
<td>16</td>
<td>18</td>
<td>12</td>
<td>23</td>
<td>4</td>
</tr>
<tr>
<td>Chronic hepatitis C (27)</td>
<td>Positive (3)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Negative (24)</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>4</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Chronic hepatitis B (23)</td>
<td>Positive (3)</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Negative (20)</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>6</td>
</tr>
</tbody>
</table>

*p-ANCA, perinuclear anti-neutrophil cytoplasmic antibodies; AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis.

‡p = 0.045 (Fisher’s exact test).
§p = 0.023 (Fisher’s exact test).

*Positive for antibodies to either HMG1 or HMG2.
†Positive for antibodies to both HMG1 and HMG2.

Figure 2

Figure 2  Titres of antibodies to HMG1 (A) and HMG2 (B) determined by ELISA. AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis. The solid lines represent median values of antibody titres. p values by Mann-Whitney U test.
staining on ethanol fixed neutrophils, cytoplasmic fluorescent patterns on formalin fixed neutrophils were detected in 24 (96%) of 25 sera from patients with AIH, 10 (62%) of 16 sera from patients with PBC, two (67%) of three sera from patients with chronic hepatitis C, and two (67%) of three sera from patients with chronic hepatitis B. The remaining sera showed negative staining. We considered these two patterns as positive for p-ANCAs as described elsewhere. Median titres of the p-ANCA positive sera were 640 (range 10–8000) for AIH and 20 (range 10–640) for PBC.

Figure 1 shows some representative results. On the other hand, c-ANCAs were only detected in 9% of PBC sera. Neither p-ANCAs nor c-ANCAs were detected in normal control sera.

ANTIBODIES TO HMG1, HMG2, CATHEPSIN G, AND LACTOFERRIN ASSAYED BY ELISA

All sera from patients with AIH, PBC, chronic hepatitis C, and chronic hepatitis B were tested for reactivity to HMG1, HMG2, cathepsin G, and lactoferrin by ELISA. Table 2 summarises the frequencies of those antibodies. Antibodies to HMG1, HMG2, and cathepsin G were more commonly detected in patients with AIH and PBC than in patients with chronic hepatitis C and B. The titres of antibodies to HMG1 and HMG2 in AIH were significantly higher than in PBC, chronic hepatitis C and B (fig 2). The titres of antibodies to HMG1 and HMG2 in PBC were significantly higher than in chronic hepatitis C and B. These positive sera for antibodies to HMG1, HMG2, cathepsin G, and lactoferrin seemed to be specific, as the preincubation of the sera with the corresponding antigens abrogated reactivity in the subsequent ELISA. Figure 3 shows representative results.

RELATIONS BETWEEN p-ANCAS AND ANTI-HMG1 AND/OR ANTI-HMG2 ANTIBODIES

In AIH, the presence of p-ANCAs correlated significantly with the presence of anti-HMG1 and/or anti-HMG2 antibodies, but not with the presence of anti-cathepsin G and anti-lactoferrin antibodies (table 2). The titres of p-ANCAs correlated significantly with the titres of anti-HMG2 antibody (fig 4) and weakly with the titres of anti-HMG1 antibody (Spearman rank correlation, r = 0.3111, p = 0.0004). From p-ANCA and anti-HMG1/HMG2 antibody positive sera of patients with AIH, we selected four specimens with negative or low titres of anti-cathepsin G or anti-lactoferrin antibodies for competitive inhibition IIF. The titres of p-ANCAs decreased after preincubation with a mixture of HMG1/HMG2 (one serum from 5120 to <320, one serum from 1280 to <320, and two from 320 to 80). Figure 5 shows representative results.

In PBC, the presence of p-ANCAs did not correlate with the presence of anti-HMG1 and/or anti-HMG2 antibodies (table 2), although titres of p-ANCAs correlated weakly with titres of anti-HMG2 antibody (Spearman rank correlation, p = 0.042).
Table 3  Relations between antibodies to HMG1/HMG2 and ANA, SMA and AMA

<table>
<thead>
<tr>
<th>Disease (n)</th>
<th>Autoantibodies (n)</th>
<th>Positive</th>
<th>Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIH (28)</td>
<td>ANA+ (25)</td>
<td>23</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>ANA− (3)</td>
<td>15</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>SMA+ (16)</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>SMA− (12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBC (44)</td>
<td>ANA+ (29)</td>
<td>24</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>ANA− (15)</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>AMA+ (33)</td>
<td>25</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>AMA− (11)</td>
<td>6</td>
<td>5</td>
</tr>
</tbody>
</table>

AHI, autoimmune hepatitis; PBC, primary biliary cirrhosis; ANA, anti-nuclear antibody; SMA, anti-smooth muscle antibody; AMA, anti-mitochondrial antibody.

*p = 0.017 (Fisher’s exact test).

Table 4 Association of anti-HMG1 or anti-HMG2 antibodies and clinical features in patients with AIH and PBC.

<table>
<thead>
<tr>
<th></th>
<th>Anti-HMG1 antibodies</th>
<th>Anti-HMG2 antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive (median value) n=22</td>
<td>Negative n=6</td>
</tr>
<tr>
<td>AST (IU/l)</td>
<td>179 112</td>
<td></td>
</tr>
<tr>
<td>ALT (IU/l)</td>
<td>144 160</td>
<td></td>
</tr>
<tr>
<td>IgG (mg/dl)</td>
<td>3234 2795</td>
<td></td>
</tr>
<tr>
<td>IgM (mg/dl)</td>
<td>297 435 p=0.025</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anti-HMG1 antibodies (median value)</th>
<th>Anti-HMG2 antibodies (median value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Men (n=86)</td>
<td>14.2 61.4 p=0.029</td>
</tr>
<tr>
<td>Women (n=22)</td>
<td></td>
</tr>
<tr>
<td>Other immunological diseases</td>
<td></td>
</tr>
<tr>
<td>+ (n=7)</td>
<td>140.8 83.5 NS</td>
</tr>
<tr>
<td>− (n=21)</td>
<td></td>
</tr>
<tr>
<td>Liver cirrhosis</td>
<td></td>
</tr>
<tr>
<td>+ (n=3)</td>
<td>28.2 34.8 NS</td>
</tr>
<tr>
<td>− (n=25)</td>
<td></td>
</tr>
<tr>
<td>Use of prednisolone at time of sampling</td>
<td></td>
</tr>
<tr>
<td>+ (n=5)</td>
<td>31.9 128.0 NS</td>
</tr>
<tr>
<td>− (n=23)</td>
<td></td>
</tr>
</tbody>
</table>

p values by Mann-Whitney U test.

AST, serum aspartate aminotransferase; ALT, serum alanine aminotransferase.

clinical parameters selected were age, sex, serum aspartate aminotransferase, alanine aminotransferase, IgG, IgM, histology, treatment, clinical course, presence of liver cirrhosis and complications of any other immunological diseases. In AIH, as shown in table 4, anti-HMG1 and anti-HMG2 antibody titres were significantly higher in women than in men. Patients with AIH with positive anti-HMG1 antibody showed lower IgM. In eleven of the 12 patients with AIH, who had high titres of anti-HMG1 or anti-HMG2 antibody before corticosteroid treatment (prednisolone, between 20 and 60 mg/day), the antibody titre returned to normal or decreased after 5–10 months of treatment (data not shown). In PBC, however, no significant relation was observed between the presence of anti-HMG1 and/or anti-HMG2 antibodies and clinical status (data not shown).

Discussion

We found that antibodies to either HMG1 or HMG2 were detected more often in patients with AIH and PBC than in those with chronic hepatitis C and B. In AIH, the titres of antibodies to either HMG1 or HMG2 were significantly higher than in PBC and chronic hepatitis C and B. Interestingly, the presence and titres of these antibodies in AIH correlated significantly with those of p-ANCA. Preincubation of sera from patients with AIH with an excess mixture of HMG1 and HMG2 resulted in a decrease in the p-ANCA titre. These results strongly suggest that HMG1 and HMG2 are significant target antigens of p-ANCAs in AIH. Indeed, anti-cathepsin G antibodies were detected more often here than in a previous study. ANA and SMA are useful seromarkers for AIH. In our study, the presence of anti-HMG1 and/or anti-HMG2 antibodies was independent of the presence of ANA and SMA. Interestingly, anti-HMG1 and/or anti-HMG2 antibodies disappeared or significantly decreased in titre after corticosteroid therapy in AIH. If the titres of anti-HMG1 and/or anti-HMG2 antibodies reflect disease activity, these antibodies can serve as useful clinical markers in AIH, because the detection systems for these antibodies are simpler and more quantitative than those for ANA and SMA. The relations between the titre of anti-HMG1 and/or anti-HMG2 antibodies and the activity index of AIH are at present being analysed in a prospective follow up study.

In PBC, anti-HMG1 and/or anti-HMG2 antibodies were detected in both p-ANCA positive patients and p-ANCA negative patients, although these antibodies were hardly detected in p-ANCA negative patients with AIH. Moreover, some monoclonal anti-HMG1 and/or anti-HMG2 antibodies showed a p-ANCA staining pattern, whereas others did not (unpublished observation). These observations suggest that anti-HMG1 and/or anti-

In Table 3, the relations between antibodies to HMG1/HMG2 and ANA, SMA, and AMA are presented. The table shows the number of sera positive for antibodies to HMG1 or HMG2 in different diseases. The data indicate that there is a positive correlation between the presence of ANA and SMA and the presence of antibodies to HMG1 and/or HMG2. However, the presence of AMA was not correlated with the presence of antibodies to HMG1 or HMG2.

In Table 4, the association of anti-HMG1 or anti-HMG2 antibodies with clinical features in patients with AIH and PBC is shown. The table includes data on sex, age, serum aspartate aminotransferase, alanine aminotransferase, IgG, IgM, histology, treatment, clinical course, and complications of any other immunological diseases. The data suggest that anti-HMG1 and anti-HMG2 antibodies are significant target antigens of p-ANCAs in AIH, and that these antibodies can serve as useful clinical markers in AIH.
HMG2 antibodies can be divided into two subtypes by IIF using ethanol fixed neutrophils: a p-ANCA staining subtype and a negative staining one. Clarifying the epitopes of these antibodies would facilitate our understanding of the pathological difference between AIH and PBC.

p-ANCAs are also commonly detected in PSC.

In our preliminary study, p-ANCA were detected in eight of 11 patients with PSC. Among p-ANCA positive patients, however, anti-HMG1 and/or anti-HMG2 antibodies were positive in only two patients (unpublished observation). It is unlikely that HMG1 and HMG2 are major p-ANCA antigens in PSC. It has been considered that the main autoimmune targets in AIH are hepatocytes, whereas those in PBC and PSC are intracellular bile capillary epithelia and bile duct epithelia respectively. Therefore the presence of anti-HMG1 and anti-HMG2 antibodies may reflect hepatocellular damage rather than bile duct epithelial damage.

The way in which HMG1 and HMG2 are involved in the pathogenesis of autoimmune liver disease is unknown. Besides its cytoplasmic and intranuclear localization, HMG1 exists on the membrane of nerve cells and plays a role in enhancing neurite outgrowth. It has also been reported that HMG1 is secreted by a murine erythrocyte leukaemia cell line. Thus, if HMG1 exists on the surface of cells or in extracellular environments at inflammatory sites, the anti-HMG1 antibody may bind to HMG1, resulting in modification of the inflammatory process in autoimmune liver diseases. It therefore seems important to determine the distribution and expression of HMG1 and HMG2 molecules in liver cells to clarify the pathological role of anti-HMG1 and anti-HMG2 antibodies.

This work was supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan, by research grants from the Ministry of Health and Welfare of Japan, and by grants from the Japan Rheumatism Association.

High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis


Gut 1999 44: 867-873
doi: 10.1136/gut.44.6.867

Updated information and services can be found at:
http://gut.bmj.com/content/44/6/867

These include:

References
This article cites 33 articles, 10 of which you can access for free at:
http://gut.bmj.com/content/44/6/867#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Hepatitis other (155)
- Hepatitis B (88)
- Hepatitis C (160)
- Pancreas and biliary tract (1949)
- Ulcerative colitis (1113)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/